Duo Oncology

Coming – December 4

Developing Nanomedicine To Redefine Cancer Treatment

Date and Time

December 4

–

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Duo Oncology is a next-generation biotech company that is creating a tumor-responsive nanomedicine platform that replaces chemotherapy for the treatment of hard-to-treat cancers. Chemo has been the standard of care for more than 50 years even though its toxicity often causes severe, treatment-limiting side effects.

Duo Oncology’s proprietary nanoparticle platform allows their drugs to slip between the cells of solid tumors. It delivers a novel chemical package that concentrates medicine deep in the tumor, improving efficacy while protecting healthy organs. The breakthrough is a prodrug polymer conjugate that creates a “shell” encapsulating a second drug. This supports synergistic killing that is hard to replicate with separate formulations.

Duo’s platform is efficient to develop, easily produced, and because it reduces off-target effects, will save payers $20K-$60K per treatment cycle by reducing the need for supportive care needed with chemo. With pre-clinical validation, and quickly advancing trials, it is well-positioned for clinical momentum and value creation.

A few highlights:
  • Duo’s lead program DUO-207 is ready for Phase 1 clinical trials targeting pancreatic cancer and other solid tumors. It has received Orphan Designations from the U.S. Food & Drug Administration and the European Medicines Agency.
  • Duo is supported by strategic institutional and operational investors as well as several awards from the National Cancer Institute (NCI).
  • The management team brings deep expertise in oncology, nanomedicine and clinical development, allowing the company to execute efficiently.

Register now for our online event with Sam Rothstein, CEO & Co-Founder of Duo Oncology, to hear how their platform offers a differentiated, high-impact solution for a large and underserved segment.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.